Mubadala Investment Co PJSC Purchases Shares of 43,908 Gilead Sciences, Inc. (NASDAQ:GILD)

Mubadala Investment Co PJSC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 43,908 shares of the biopharmaceutical company's stock, valued at approximately $4,056,000. Gilead Sciences makes up approximately 0.0% of Mubadala Investment Co PJSC's holdings, making the stock its 17th biggest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC raised its stake in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This trade represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 25,429 shares of company stock valued at $2,894,445 in the last ninety days. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on GILD shares. Royal Bank of Canada lifted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Trading Up 2.2%

GILD traded up $2.16 during midday trading on Friday, hitting $102.50. 6,395,303 shares of the company were exchanged, compared to its average volume of 7,677,426. The firm's 50 day moving average price is $105.75 and its 200-day moving average price is $99.76. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market capitalization of $127.50 billion, a P/E ratio of 277.03, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the firm posted ($1.32) EPS. The company's revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 3.08%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.